Article History
Received: 20 October 2019
Accepted: 1 December 2019
First Online: 8 January 2020
Change Date: 4 March 2020
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake. There was a typographical error in Figure 1: “Nebulization time ≤ 30 min” (first light blue square) should be replaced by “Nebulization time ≤ 90 min”. The authors apologize for the mistake.
Compliance with ethical standards
:
: JR received grant support from BAYER and served in the advisory board for BAYER and speakers bureau for Norma Helas. OM served as a consultant for SANOFI. SE declares having received consultancies from Aerogen Ltd, La Diffusion Technique Française and Bayer Healthcare, research support from Aerogen Ltd, Fisher & Paykel healthcare, Hamilton medical, travel reimbursements from Aerogen Ltd and Fisher & Paykel. JD and PFL received an unrestricted grant from Aerogen Ltd for their study []. JMQ currently received grant from Sino-European Cooperative Clinical Research Project “Evaluation of clinical efficacy and safety of QBW251 in patients with severe bronchiectasis”. MB has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, Bayer, Basilea, Biomerieux, Cidara, Gilead, Menarini, MSD, Nabriva, Paratek, Pfizer, Roche, Melinta, Shionogi, Tetraphase, VenatoRx and Vifor and has received study grants from Angelini, Basilea, Astellas, Shionogi, Cidara, Melinta, Gilead, Pfizer and MSD. JAR has received grants or consultancy fees from MSD, Accelerate Diagnostics, Biomerieux, Pfizer, The Medicines Company and Cardeas Pharma. KP has received speaker’s Honoraria from MSD and Pfizer. GD has received grants and speaker’s Honoraria from Pfizer, InfectoPharma, Virogates, Glenmark india, Clinigen, Nabriva, Menarini and ELPEN. AK has received research grant from Norma Helas. The other authors declare no conflict of interest.
: An approval by an ethics committee was not applicable.
Free to read: This content has been made available to all.